Vol 10, No 6 (2013)

This review is devoted to skin barrier function of epidermis, factors underlying xerosis, clinical features of kuperosis, case report of rosaceae as an example of skin barrier function abnormality is presented.

Background. Determination of local epithelial cells expressing TLR2 as an indicator of local immunity in allergic rhinitis (AR) patients with opportunistic species of staphylococci nasal mucosa colonization. Methods. Washed epithelium samples obtained from patients with seasonal AR (n=8) aged 19—42 years, and perennial AR (n=15) aged 19 —45 years, as well as a control group (20 patients) aged 19—45 years without allergic diseases were investigated. Epithelial cells expressing TLR2 receptors were determined by flow cytometry. Results. The level of epithelial cells expressing TLR2 receptor in patients with seasonal AR was almost in 1,9 times, in perennial AR group — in 1,7 times lower then in healthy individuals. In patients with perennial AR S. aureus was obtained in 96,0% (CI: 79,5—99,2), in association with Str. pyogenes in 29% (CI: 14,9—49,2), Neisseria spp. — in 63,0% (CI: 42,7—78,8). Seasonal allergic rhinitis was characterized by association of S. aureus and S. hemolyticus (70,0%, 44,4—85,8). Conclusion. Ratio of epithelial cells positive for TLR2 in nasal lavage from patients with AR was lower than in healthy volunteers. Indicators proportion of epithelial cells expressing TLR2 in nasal lavage in patients with seasonal AR during an exacerbation period was significantly reduced (1,7—1,9 times), in comparison with healthy volunteers. In AR patients with increased density of staphylococci strains in nasal mucosa increased local epithelial cells expressing TLR2 in nasal lavage was established.

Beclomethasone dipropionate (BDP, Clenil UDV) is a well-studied inhaled corticosteroid for the treatment of patients with bronchial asthma (BA). Randomized controlled trials have shown that nebulized therapy with BDP was similar in its efficacy and safety to inhalation therapy with budesonide or fluticasone. Preferred patients for the treatment with nebulized BDP are elderly patients with asthma, unable to correctly perform inhalation with portable devices, patients with steroid-dependent asthma, and patients with a temporary loss of asthma control.

The article presents the results of a prospective noncomparative study of use of carbamylated monomeric allergoid Lais ® for sublingual immunotherapy (SLIT) in patients with allergic rhinoconjunctivitis caused by pollen grasses. We suggest that SLIT with Lais ® sublingual tablets is an effective and welltolerated form of treatment.

The aim of this study was to reveal most clinically effective and economically expedient anti-H 1-receptor antagonist cetirizine generation (original or generic), to carry out the analysis of pharmaceutical equivalence of cetirizine generation anti-H-receptor antagonists manufactured by different companies. Materials and methods. Study is executed in design of simple open comparative prospective randomized research in parallel groups. The preliminary analysis of volume and structure of H-antihistamine cetirizine generation products retails for the purpose of definition of the most widespread trademarks was carried out 117 patients with chronic idiopathic urticaria (CIU) treated with various trademarks cetirizine 10 mg/day within 4 weeks were included in the study. Clinical efficiency criteria: dynamics of urticaria symptoms, change of index severity, remission period, days free from CIU symptoms. The pharmaceutical analysis included comparative studying of rate of dissolution and quantitative identification of medicinal substance. The pharmacoeconomic analysis was done by an «expense-efficiency» method. Results. All investigated drugs of cetirizine in a dose of 10 mg dayly significantly (p<0,001) reduced CIU symptoms. In mild CIU clinical efficiency of original and generic drugs had no significant differences but in severe CIU showed obvious superiority of an original drug (p<0,01). The greatest quantity of the patients reached pharmacological remission, received Zirtec and Cetrine. Coincidence of dissolution profiles with criteria of similarity for Zirtec, Cetrine and Parlazine and rate of substance liberation for Zirtec and Cetrine explained rapidity of achievement of therapeutic effect of investigated preparations. The best results from the point of view of economic efficiency were shown with Cetrine therapy. Use of original Zirtec was more expensive, but also more effective. Discussion. Results of the study demonstrated clinical efficiency of cetirizine family products belonged to different manufacturers depending on their bioavailability which had the following rating of efficiency: Cetrine > Parlazine > Cetirizine-Hexal > Zodak.